BRCA1 and BRCA2 hereditary breast carcinoma phenotypes

Cancer

Volumn 80, Issue 3 SUPPL., 1997, Pages 543-556

  Marcus, Joseph N ^a   Page, David L ^b   Watson, Patrice ^c   Narod, Steven A ^d   Lenoir, Gilbert M ^e   Lynch, Henry T ^c  

^a ST LUKE S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANEUPLOIDY; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CONFERENCE PAPER; GENE MUTATION; HUMAN; MITOSIS RATE; PRIORITY JOURNAL;

EID: 0030811692     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19970801)80:3+<543::aid-cncr4>3.0.co;2-a     Document Type: Conference Paper

References (110)

1. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1996;268:1749-53.
2. Malkin D, Li FP, Strong C, Fraumeni JF Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
3. Nelen MR, Padberg GW, Peeters EAJ, Lin AY, van den Helm B, Frants RR, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996;13:114-6.
4. Broca PP. Traité des tumeurs. Paris: Asselin, 1866.
5. Lynch HT, Krush AJ, Lemon HM, Kaplan AR, Condit PT, Bottomley RH. Tumor variation in families with breast cancer. JAMA 1972;222:1631-5.
6. Lynch HT, Marcus JN, Watson P, Lynch J. Familial breast cancer, family cancer syndromes, and predisposition to breast neoplasia. In: Bland KI, Copeland EM III, editors. The breast: comprehensive management of benign and malignant diseases. Philadelphia: W.B. Saunders Co., 1991:262-91.
7. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
8. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;65:5-25.
9. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset breast cancer to chromosome 17q21. Science 1990;250:1684-9.
10. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, et al. Familial breast-ovarian cancer locus on chromosome 17q12-23. Lancet 1991;338:82-3.
11. Miki Y, Swensen J, Shattuck-Edens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
12. Wooster R, Heuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-91.
13. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
14. Friend S, Borresen AL, Brody L, Casey G, Devilee P, Gayther S, et al. Breast cancer information on the web [letter]. Nat Genet 1995;11:238-9.
15. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 1996;13:245-7.
16. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 1995;273:535-41.
17. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins F, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995;11:198-200.
18. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-62.
19. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
20. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
21. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996;13:238-40.
22. Thor AD, Moore II DH, Edgerton SM, Kawaski ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
23. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, et al. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 1990;50:7184-9.
24. Smith SA, Easton DF, Evans DGR, Ponder BAJ. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type allele. Nat Genet 1992;2:128-31.
25. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995;10:1673-5.
26. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-50.
27. Rao VN, Shao N, Ahmad M, Reddy ESP. Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts. Oncogene 1996;12:523-8.
28. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King M-C, et al. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996;12:298-302.
29. Gudas JM, Li T, Nguyen H, Jensen D, Rauscher III FJ, Cowan K. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. Cell Growth Differ 1996;7:717-23.
30. Vaughn JP, Davis PL, Jarboe MD, Hyper G, Evans AC, Wiseman RW, et al. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 1996;7:711-5.
31. Chen Y, Farmer AA, Chen C-F, Jones DC, Chen P-L, Lee W-H. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 1996;56:3168-72.
32. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996;13:1-7.
33. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, et al. The developmental pattern of Brcal expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
34. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 1995;9:2712-22.
35. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat Genet 1995;12:191-4.
36. Gudas JM, Nguyen H, Li T, Cowan K. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561-5.
37. Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 1996;13:1639-45.
38. Chen Y, Chen C-F, Riley DJ, Allred DC, Chen P-L, Von Hoff D, et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995;270:789-91.
39. Jensen RA, Thompson ME, Jetton TL, Szabo CI, van der Meer R, Helou B, et al. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 1996a;12:303-8.
40. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, et al. Localization of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:123-5.
41. Chen Y, Chen P-L, Riley DJ, Lee W-H, Allred DC, Osborne CK. Localization of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:125-6.
42. Jensen RA, Thompson ME, Jetton TL, van der Meer R, Helou B, Arteage CL, et al. ...And secreted tumor suppressors. Nat Gener 1996;13:268-72.
43. Lu M, Conzen SD, Cole CN, Arrick BA. Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res 1996;56:4578-1.
44. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, et al. Cell cycle control of BRCA2. Cancer Res 1996;56:4590-4.
45. Narod SA, Ford D, Devilee P, Barkadottir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995;56:254-64.
46. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-5.
47. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995;56:265-71.
48. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, et al. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995;11:428-33.
49. Serova O, Montagna M, Torchard D, Narod SA, Tonin P, Sylla B, et al. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 1996;58:42-51.
50. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 1996;12:309-11.
51. Gudmundsson J, Johannesdottir G, Arason A, Bergthorsson JT, Ingvarsson S, Egilsson V, et al. Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. Am J Hum Genet 1996;58:749-56.
52. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996;13:117-9.
53. Grimmond SM, Palmer JM, Walters MK, Scott C, Nancarrow DJ, Teh BT, et al. Confirmation of a susceptibility locus on chromosome 13 in Australian breast cancer families. Hum Genet 1996:98:80-5.
54. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996;56:3363-5.
55. Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996;13:120-2.
56. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found In both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 1996;56:3409-14.
57. Boyd J. BRCA2 as a low-penetrance cancer gene. J Natl Cancer Inst 1996;88:1408-9.
58. Takahashi H, Chiu HC, Bandera CA, Behbakht K, Liu PC, Couch FJ, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738-41.
59. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-7.
60. Mulcahy GM, Platt R. Pathologic aspects of familial carcinoma of the breast. In: Lynch HT, editor. Genetics and breast cancer. New York: Van Nostrand Reinhold, 1981:65-97.
61. Marcus JN, Watson P, Page DL, Lynch HT. The pathology and heredity of breast cancer in younger women. Monogr J Natl Cancer Inst 1994;16:23-34.
62. Lynch HT, Lemon SJ, Marcus JN, Lerman C, Lynch J, Narod S. Breast cancer genetics: heterogeneity, molecular genetics syndrome diagnosis, and genetic counseling. In: Bland KI, Copeland EM III, editors. The breast: comprehensive management of benign and malignant diseases. 2nd edition. Philadelphia: W.B. Saunders Co., 1997. In press.
63. Anderson DE. Genetic study of breast cancer. Identification of a high risk group. Cancer 1974;34:1090-7.
64. Rosen PP, Lesser ML, Senie MA, Kinne DW. Epidemiology of breast carcinoma III: relationship of family history to tumor type. Cancer 1982;50:171-9.
65. Marcus J, Page D, Watson P, Conway T, Lynch H. High mitotic grade in hereditary breast cancer. Lab Invest 1988;56:61A.
66. Marcus J, Watson P, Linder-Stephenson L, Conway T, Page D, Lynch H. The pathobiology of BRCA1-linked and -unlinked hereditary breast cancer (HBC). Mod Pathol 1994;7:18A.
67. Meyer JS, Prey MU, Babcock DS, McDivitt RW. Breast carcinoma cell kinetics, morphology, stage, and host characteristics: a thymidine labeling study. Lab Invest 1986;54:41-51.
68. Erdreich LS, Asal NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. South Med J 1980;73:28-32.
69. LiVolsi VA, Kelsey JL, Fischer DB, Holford TR, Mostow ED, Goldenberg IS. Effect of age at first childbirth on risk of developing specific histologie subtype of breast cancer. Cancer 1982;49:1937-40.
70. Stalsberg H, Thomas DB, Noonan EA, The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Histologie types of breast carcinoma in relation to international variation and breast cancer risk factors. Int J Cancer 1989;44:399-409.
71. Lagios MD, Rose MR, Margolin FR. Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol 1980;73:25-30.
72. Mosimann S, Torhorst JKH, Weber W, Müller H. Histopathological aspects of familial breast cancer. In: Weber W, Laffer UT, Dürig M, editors. Hereditary cancer and preventive surgery. Basel: Karger, 1990:1-7.
73. Haagensen CD. Family history of breast carcinoma in women predisposed to develop breast carcinoma. J Natl Cancer Inst 1972;48:1025-7.
74. Claus EB, Risch N, Thompson WD, Carter D. Relationship between breast histopathology and family history of breast cancer. Cancer 1993;71:147-53.
75. Lynch HT, Marcus J, Watson P, Page D. Distinctive clinicopathologic features of BRCA1-linked hereditary breast cancer. Proc Am Soc Clin Oncol 1994;13:56.
76. Marcus J, Watson P, Page D, Narod S, Linder-Stephenson L, Conway T, et al. Tubular-lobular group (TLGJ carcinomas as a signature of the BRCA2 gene in inherited breast cancer. Mod Pathol 1995;8:21A.
77. Marcus J, Linder-Stephenson L, Conway T, Abels K, Watson P, Page D, et al. High S phase fraction in hereditary breast carcinoma. Cytometry 1993;14(Suppl 6):34.
78. Jacquemier J, Eisinger F, Birnbaum D, Sobol H. Histoprognostic grade in BRCA1-associated breast cancer [letter]. Lancet 1995;345:1503.
79. Bignon Y-J, Fonck Y, Chassagne M-C. Histoprognostic grade in tumors from families with hereditary predisposition to breast cancer [letter]. Lancet 1995;346:258.
80. Gusterson BA, Stratton MR, Anbazhagan R. The importance of human breast development in mammary carcinogenesis. In: Li SA, Gustafsson JA, Nandi S, Sekely LI, editors. Hormonal carcinogenesis: proceedings of the second international symposium. New York: Springer, 1991:115-9.
81. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat. In press.
82. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
83. Caligo MA, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, et al. BRCA1 germline mutational spectrum in families from Tuscany: a high frequency of novel mutations. Oncogene 1996;13:1483-8.
84. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets BB, Peyrat J-P, Kerangueven F, Janin N, et al. Truncation at conserved terminal regions of the BRCA1 protein is associated with highly proliferating hereditary breast cancers. Cancer Res 1996;56:3216-9.
85. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1 [letter]. Lancet 1996;348:408.
86. Jacquemier J, Eisinger F, Guinebretiere J-M, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer [letter]. Lancet 1996;348:1098.
87. Jacquemier J, Seradour B, Hassoun J, Piana L. Special morphologic features of invasive mammary carcinomas in women under 40 years of age. Breast Dis Senol 1985;1:119-22.
88. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232-9.
89. Sigurdsson H, Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Gudlaugsdottir S, et al. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene. Breast Cancer Res Treat 1996;37(Suppl):33.
90. Albano WA, Recabaren JA, Lynch HT, Campbell AS, Mailliard JA, Organ CH, et al. Natural history of hereditary cancer of the breast and colon. Cancer 1982;50:360-3.
91. Malone KE, Daling JR, Weiss NS, McKnight B, White E, Voigt LF. Family history and survival of young women with invasive breast carcinoma. Cancer 1996;78:1417-25.
92. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993;341:184-5.
93. Porter DE, Cohen BB, Wallace MR, Smyth E, Dixon M, Steel CM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
94. Olsson H, Ranstam J, Baldetorp B, Ewers S-B, Fernö M, Killander D, et al. Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer 1991;67:1285-90.
95. Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha K, Giles HR, et al. Model for the genetic evolution of solid tumors. Cancer Res 1989;49:3344-54.
96. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
97. Dutrillaux B, Gerbault-Seureau M, Remvikos Y, Zafrani B, Prieur M. Breast cancer genetic evolution: I. Data from cytogenetics and DNA content. Breast Cancer Res Treat 1991;19:245-55.
98. Cornelisse CJ, Kuipers-Dijkhoorn N, van Vliet M, Hermans J, Devilee P. Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss. Int J Cancer 1992;50:544-8.
99. Remvikos Y, Gerbault-Seureau M, Magdelénat H, Prieur M, Dutrillaux B. Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat 1992;23:43-9.
100. Visscher DW, Zarbo RJ, Greenawald KA, Crissman JD. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. Pathol Annu 1990;25(1):171-210.
101. Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-85.
102. Baucus SS, Zelnick CR, Chin DM, Yarden Y, Kaminsky DB, Benington J, et al. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. Am J Pathol 1994;145:1337-48.
103. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol 1992;11:180-7.
104. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
105. Borg A, Zhang Q-X, Johannsson O, Olsson H. High frequency of allelic imbalance at the BRCA1 region on chromosome 17q in both familial and sporadic ductal breast carcinomas. J Natl Cancer Inst 1994;86:792-4.
106. Jones JL, Royall JE, Walker RA. E-cadherin relates to EGRF expression and lymph node metastasis in primary breast carcinoma. Br J Cancer 1996;74:1237-41.
107. Aldaz CM, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995;55:3976-81.
108. Glebov OK, McKenzie KE, White CA, Sukumar S. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 1994;54:3703-9.
109. Paulson TG, Wright FA, Parker BA, Russack V, Wahl GM. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res 1996;56:4021-6.
110. Lynch HT, Smyrk T. Colorectal cancer, survival advantage, and hereditary nonpolyposis colorectal carcinoma. Gastroenterology 1996;110:943-7.